Negative regulation of DAB2IP by Akt and SCFFbw7 pathways

被引:31
作者
Dai, Xiangping [1 ]
North, Brian J. [1 ]
Inuzuka, Hiroyuki [1 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA
关键词
DAB2IP; Akt; Fbw7; degradation; cancer; phosphorylation; ubiquitination; ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; UBIQUITIN-PROTEASOME SYSTEM; PROSTATE-CANCER; TUMOR-SUPPRESSOR; DOWN-REGULATION; EXPRESSION; DESTRUCTION; METASTASIS; COMPLEX;
D O I
10.18632/oncotarget.1939
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP), is a tumor suppressor that serves as a scaffold protein involved in coordinately regulating cell proliferation, survival and apoptotic pathways. DAB2IP is epigenetically down-regulated in a variety of tumors through the action of the histone methyltransferase EZH2. Although DAB2IP is transcriptionally down-regulated in a variety of tumors, it remains unclear if other mechanisms contribute to functional inactivation of DAB2IP. Here we demonstrate that DAB2IP can be functionally down-regulated by two independent mechanisms. First, we identified that Akt1 can phosphorylate DAB2IP on S847, which regulates the interaction between DAB2IP and its effector molecules H-Ras and TRAF2. Second, we demonstrated that DAB2IP can be degraded in part through ubiquitin-proteasome pathway by SCFFbw7. DAB2IP harbors two Fbw7 phosho-degron motifs, which can be regulated by the kinase, CK1 delta. Our data hence indicate that in addition to epigenetic down-regulation, two additional pathways can functional inactivate DAB2IP. Given that DAB2IP has previously been identified to possess direct causal role in tumorigenesis and metastasis, our data indicate that a variety of pathways may pass through DAB2IP to govern cancer development, and therefore highlight DAB2IP agonists as potential therapeutic approaches for future anti-cancer drug development.
引用
收藏
页码:3307 / 3315
页数:9
相关论文
共 32 条
[1]   The ubiquitin proteasome system - Implications for cell cycle control and the targeted treatment of cancer [J].
Bassermann, Florian ;
Eichner, Ruth ;
Pagano, Michele .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2014, 1843 (01) :150-162
[2]   A Perspective on Cancer Cell Metastasis [J].
Chaffer, Christine L. ;
Weinberg, Robert A. .
SCIENCE, 2011, 331 (6024) :1559-1564
[3]   Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer [J].
Chen, H ;
Tu, SW ;
Hsieh, JT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (23) :22437-22444
[4]   Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines [J].
Chen, H ;
Toyooka, S ;
Gazdar, AF ;
Hsieh, JT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (05) :3121-3130
[5]   Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia:: Cloning and characterization [J].
Chen, H ;
Pong, RC ;
Wang, Z ;
Hsieh, JT .
GENOMICS, 2002, 79 (04) :573-581
[6]   The ubiquitin-proteasome system and cancer [J].
Devoy, A ;
Soane, T ;
Welchman, R ;
Mayer, RJ .
ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 :187-203
[7]   Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer [J].
Dote, H ;
Toyooka, S ;
Tsukuda, K ;
Yano, M ;
Ouchida, M ;
Doihara, H ;
Suzuki, M ;
Chen, H ;
Hsieh, JT ;
Gazdar, AF ;
Shimizu, N .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2082-2089
[8]   Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour [J].
Dote, H ;
Toyooka, S ;
Tsukuda, K ;
Yano, M ;
Ota, T ;
Murakami, M ;
Naito, M ;
Toyota, M ;
Gazdar, AF ;
Shimizu, N .
BRITISH JOURNAL OF CANCER, 2005, 92 (06) :1117-1125
[9]   Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1 [J].
Gao, Daming ;
Inuzuka, Hiroyuki ;
Tseng, Alan ;
Wei, Wenyi .
CELL DIVISION, 2009, 4
[10]  
Goncharuk Viktor N, 2004, Ann Diagn Pathol, V8, P6, DOI 10.1016/j.anndiagpath.2003.11.002